The American Heart Association Updates its Guideline "Prevention of Viridans Group Streptococcal Infective Endocarditis"

The American Heart Association (AHA) has updated  its 2007 guideline Prevention of Viridans Group Streptococcal Infective Endocarditis: A Scientific Statement from the American Heart Association. The 2021 AHA scientific statement on prevention and infective endocarditis no longer recommends the use of clindamycin as an oral or parenteral alternative to amoxicillin or ampicillin in individuals with allergies to these drugs because clindamycin “may cause more frequent and severe reactions than other antibiotic used for [antibiotic prophylaxis]” (including C. difficile infection). The AHA continues to recommend infective endocarditis prophylaxis only for categories of patients at highest risk for adverse outcome. The current medication regimes recommended (when indicated) are listed in Table 2 of the 2021 AHA scientific statement (linked above).

To learn more view prevention of infective endocarditis: ADA oral health topics- antibiotics-prophylaxis